Graham Capital Management L.P. Takes $1.08 Million Position in Edwards Lifesciences Corporation $EW

Graham Capital Management L.P. acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 14,933 shares of the medical research company’s stock, valued at approximately $1,082,000.

A number of other hedge funds have also recently modified their holdings of EW. Nuveen LLC bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at $330,881,000. Jennison Associates LLC boosted its holdings in Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after buying an additional 2,576,383 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Edwards Lifesciences in the 4th quarter worth $92,631,000. Orbimed Advisors LLC bought a new position in Edwards Lifesciences in the 4th quarter worth $84,787,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Edwards Lifesciences by 24.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 4,615,163 shares of the medical research company’s stock worth $341,661,000 after buying an additional 921,500 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.6%

EW opened at $81.25 on Thursday. The firm has a 50-day simple moving average of $78.63 and a two-hundred day simple moving average of $75.14. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $47.70 billion, a PE ratio of 11.69, a price-to-earnings-growth ratio of 3.92 and a beta of 1.07. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,014 shares of company stock worth $1,698,844 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on EW shares. Evercore ISI upped their target price on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a report on Friday, July 25th. Argus raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Wall Street Zen raised shares of Edwards Lifesciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 30th. Truist Financial upped their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Finally, Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.